Ionis Pharmaceuticals Inc...

28.50
-0.21 (-0.73%)
At close: Apr 03, 2025, 3:59 PM
27.61
-3.11%
Pre-market: Apr 04, 2025, 07:26 AM EDT

Ionis Pharmaceuticals Statistics

Share Statistics

Ionis Pharmaceuticals has 158.97M shares outstanding. The number of shares has increased by 8.91% in one year.

Shares Outstanding 158.97M
Shares Change (YoY) 8.91%
Shares Change (QoQ) 0.68%
Owned by Institutions (%) 99.99%
Shares Floating 154.59M
Failed to Deliver (FTD) Shares 5.01K
FTD / Avg. Volume 0.3%

Short Selling Information

The latest short interest is 10.24M, so 6.49% of the outstanding shares have been sold short.

Short Interest 10.24M
Short % of Shares Out 6.49%
Short % of Float 7.04%
Short Ratio (days to cover) 6.49

Valuation Ratios

The PE ratio is -11.52 and the forward PE ratio is -12.36. Ionis Pharmaceuticals's PEG ratio is -0.61.

PE Ratio -11.52
Forward PE -12.36
PS Ratio 7.41
Forward PS 1.9
PB Ratio 8.88
P/FCF Ratio -9.57
PEG Ratio -0.61
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ionis Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.47, with a Debt / Equity ratio of 2.39.

Current Ratio 8.47
Quick Ratio 8.43
Debt / Equity 2.39
Debt / EBITDA -2.96
Debt / FCF -2.58
Interest Coverage -5.63

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $659.62K
Profits Per Employee $-424.6K
Employee Count 1,069
Asset Turnover 0.23
Inventory Turnover 0.9

Taxes

Income Tax -6.17M
Effective Tax Rate 1.34%

Stock Price Statistics

The stock price has increased by -33.46% in the last 52 weeks. The beta is 0.28, so Ionis Pharmaceuticals's price volatility has been higher than the market average.

Beta 0.28
52-Week Price Change -33.46%
50-Day Moving Average 32.27
200-Day Moving Average 39.09
Relative Strength Index (RSI) 35.74
Average Volume (20 Days) 1.67M

Income Statement

In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.9M in profits. Earnings per share was -3.04.

Revenue 705.14M
Gross Profit 693.92M
Operating Income -475.08M
Net Income -453.9M
EBITDA -475.08M
EBIT -477.06M
Earnings Per Share (EPS) -3.04
Full Income Statement

Balance Sheet

The company has 242.08M in cash and 1.41B in debt, giving a net cash position of -1.17B.

Cash & Cash Equivalents 242.08M
Total Debt 1.41B
Net Cash -1.17B
Retained Earnings -2.25B
Total Assets 3B
Working Capital 2.31B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -500.95M and capital expenditures -45.28M, giving a free cash flow of -546.23M.

Operating Cash Flow -500.95M
Capital Expenditures -45.28M
Free Cash Flow -546.23M
FCF Per Share -3.65
Full Cash Flow Statement

Margins

Gross margin is 98.41%, with operating and profit margins of -67.37% and -64.37%.

Gross Margin 98.41%
Operating Margin -67.37%
Pretax Margin -65.25%
Profit Margin -64.37%
EBITDA Margin -67.37%
EBIT Margin -67.37%
FCF Margin -77.46%

Dividends & Yields

IONS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for IONS is $61, which is 114% higher than the current price. The consensus rating is "Buy".

Price Target $61
Price Target Difference 114%
Analyst Consensus Buy
Analyst Count 19
Stock Forecasts

Scores

Altman Z-Score 0.75
Piotroski F-Score 2